EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review

Ying Liu, Mingyang Li, Yu Guo, Zhiyong Zhang, Liuyang Du, Xiaotong Zhang, Yingping Wang, Dong Zhang, Lingfei Xue, Binhua Lei, Jing Su, Ruiwen Zhang und 4 weitere

Pathology - Research and Practice · 2024

DOI: 10.1016/j.prp.2024.155371 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Ying Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine Center, Sanmenxia Central Hospital, Sanmenxia, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Indoles. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Targeted therapy with combined dabrafenib and trametinib has been proven to provide clinical benefits in patients with BRAF V600E mutation-positive NSCLC. Nevertheless, the treatment strategy for NSCLC patients with BRAF non-V600E mutations remains limited. CASE PRESENTATION: Here, we present a NSCLC patient with a BRAF N581S mutation, which is a class III BRAF mutation, and this patient had a durable response to targeted therapy with combined anlotinib and tislelizumab. CONCLUSION: We hope to bring more attention to rare non-V600 BRAF mutations by presenting this case of NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsIndolesLung NeoplasmsProto-Oncogene Proteins B-rafQuinolinesHumansCarcinoma, Non-Small-Cell LungMutationTreatment Outcome

Stichwörter der Autor:innen

AdenocarcinomaAnlotinibBRAF N581S mutationCase reportTislelizumab

Substanzen

anlotinibAntibodies, Monoclonal, HumanizedBRAF protein, humanIndolesProto-Oncogene Proteins B-rafQuinolinestislelizumab

Autor:innen und Institutionen

  • Department of Precision Medicine Center, Sanmenxia Central Hospital, Sanmenxia, China.
  • State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, Xi'an, China.
  • Department of Traditional Chinese Medicine, Sanmenxia Central Hospital, Sanmenxia, China.
  • Department of Statistics Branch, Sanmenxia Central Hospital, Sanmenxia, China.
  • Department of Oncology, Sanmenxia Central Hospital, Sanmenxia, China.
  • Department of Reproductive Medicine, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China. Electronic address: 361400283@qq.com.

Zitieren

APA

Liu, Y., Li, M., Guo, Y., Zhang, Z., Du, L., Zhang, X., Wang, Y., Zhang, D., Xue, L., Lei, B., Su, J., Zhang, R., Chen, J., Zhang, X., Jia, Q., & Tian, C. (2024). A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155371

Vancouver

Liu Y, Li M, Guo Y, Zhang Z, Du L, Zhang X, et al. A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155371

BibTeX
@article{Liu2024,
  author = {Liu, Ying and Li, Mingyang and Guo, Yu and Zhang, Zhiyong and Du, Liuyang and Zhang, Xiaotong and Wang, Yingping and Zhang, Dong and Xue, Lingfei and Lei, Binhua and Su, Jing and Zhang, Ruiwen and Chen, Jiaohong and Zhang, Xiangqian and Jia, Qingge and Tian, Chuntao},
  title = {A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review},
  journal = {Pathology - Research and Practice},
  year = {2024},
  doi = {10.1016/j.prp.2024.155371}
}
Kostenlos starten →